U.S. Food and Drug Administration Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS® (mavacamten) Label Read more about U.S. Food and Drug Administration Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS® (mavacamten) Label
Daxor Accelerates Blood Volume Analysis Adoption with the Launch of ezBVA Lab Services Read more about Daxor Accelerates Blood Volume Analysis Adoption with the Launch of ezBVA Lab Services
Andexxa Phase IV trial stopped early after achieving pre-specified criteria on haemostatic efficacy versus usual care Read more about Andexxa Phase IV trial stopped early after achieving pre-specified criteria on haemostatic efficacy versus usual care
INJECTAFER® Approved in the U.S. for the Treatment of Iron Deficiency in Adult Patients with Heart Failure Read more about INJECTAFER® Approved in the U.S. for the Treatment of Iron Deficiency in Adult Patients with Heart Failure
Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure Read more about Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure
Cytokinetics Presents New Data in Patients With Non-Obstructive HCM From Cohort 4 of REDWOOD-HCM in Late-Breaking Clinical Trial Session at The European Society of Cardiology Heart Failure 2023 Congress Read more about Cytokinetics Presents New Data in Patients With Non-Obstructive HCM From Cohort 4 of REDWOOD-HCM in Late-Breaking Clinical Trial Session at The European Society of Cardiology Heart Failure 2023 Congress
New Study Demonstrates Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in Heart Failure Outcomes Read more about New Study Demonstrates Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in Heart Failure Outcomes
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4021586 Read more about Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4021586
FARXIGA extended in the US to reduce risk of cardiovascular death and hospitalization for heart failure to a broader range of patients Read more about FARXIGA extended in the US to reduce risk of cardiovascular death and hospitalization for heart failure to a broader range of patients
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM) Read more about Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)